Nelson Sun Sells 14,754 Shares of Aardvark Therapeutics (NASDAQ:AARD) Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) insider Nelson Sun sold 14,754 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $5.00, for a total value of $73,770.00. Following the transaction, the insider owned 97,475 shares of the company’s stock, valued at $487,375. This represents a 13.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Nelson Sun also recently made the following trade(s):

• On Friday, September 11th, Nelson Sun sold 62,000 shares of Aardvark Therapeutics stock. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00.

Aardvark Therapeutics Stock Performance

Shares of AARD opened at $5.13 on Friday. The stock has a market capitalization of $112.24 million, a PE ratio of -1.60 and a beta of 3.74. The company’s fifty day moving average is $6.29 and its 200 day moving average is $5.53. Aardvark Therapeutics, Inc. has a fifty-two week low of $3.35 and a fifty-two week high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.21. As a group, research analysts forecast that Aardvark Therapeutics, Inc. will post -3.17 earnings per share for the current year.

Key Stories Impacting Aardvark Therapeutics

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: No company-specific clinical, regulatory, or financial improvement was reported in the latest updates. The absence of new adverse operating news may limit additional selling pressure.
• Neutral Sentiment: Several law firms—including Hagens Berman, Rosen Law Firm, SBS Law, Pomerantz, Faruqi & Faruqi, and Bernstein Liebhard—are soliciting investors to seek lead-plaintiff status by October 13, 2026. These announcements largely repeat the same underlying lawsuit rather than representing separate cases. Hagens Berman investor notice
• Neutral Sentiment: A reported September short-interest update showed zero shares sold short, but the figures appear incomplete or unreliable because the reported change was listed as “NaN.” It therefore provides little useful insight into trading direction.
• Negative Sentiment: The securities class action covers investors who bought Aardvark shares in or traceable to the February 2025 IPO, or who purchased securities between February 13, 2025, and May 14, 2026. The litigation alleges violations of federal securities laws by the company and certain officers and directors. Pomerantz class-action announcement
• Negative Sentiment: One investor notice alleges that IPO materials described Aardvark’s ARD-101 drug candidate as 99% restricted to the gut and reported no serious adverse events, while allegedly omitting safety risks that later led to an FDA clinical hold. These remain allegations, but the claims create potential legal costs, uncertainty, and reputational damage. AARD shareholder alert

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. HC Wainwright restated a “neutral” rating and issued a $6.00 price target on shares of Aardvark Therapeutics in a research report on Monday, July 20th. Wall Street Zen upgraded shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings upgraded shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $15.33.

Institutional Investors Weigh In On Aardvark Therapeutics

Hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP purchased a new position in shares of Aardvark Therapeutics during the second quarter valued at $138,000. J. Goldman & Co LP purchased a new stake in Aardvark Therapeutics in the second quarter worth about $233,000. Ieq Capital LLC purchased a new stake in Aardvark Therapeutics in the second quarter worth about $221,000. BlackRock Inc. bought a new position in Aardvark Therapeutics during the 2nd quarter worth about $1,077,000. Finally, Renaissance Technologies LLC bought a new position in Aardvark Therapeutics during the 1st quarter worth about $267,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.